Navigation Links
Data Show Vaprisol(R) Is Effective & Safe in Promptly Increasing Serum Sodium Levels in Patients With Euvolemic or Hypervolemic Hyponatremia
Date:10/10/2007

sults from a randomized controlled trial (RCT) of 84 patients and an open-label study (OLS) of 251 patients, all with euvolemic or hypervolemic hyponatremia.

After infusion of a 20 mg loading dose or placebo, Vaprisol was given in a continuous 4-day infusion of 40 or 80 mg/d in the RCT and 20 or 40 mg/d in the OLS. The pooled analysis evaluated the frequency of overly rapid [Na+] increases during Vaprisol clinical trials. Note: Overly rapid [Na+] increase can lead to serious neurologic sequelae associated osmotic demyelinization syndrome. This study defined overly rapid increase of serum [Na+] as an increase in serum [Na+] > 12 mEq/L in 24 hours.

In both studies, baseline characteristics were largely similar between those who had an overly rapid increase in [Na+] and those who did not. Among patients who received Vaprisol in the RCT, the mean change in [Na+] was significantly higher compared to the placebo group throughout the 4-day course of treatment. In the OLS, both doses of Vaprisol produced prompt increases that were sustained throughout the 4-day study. The median time to a

confirmed greater than or equal to 4 mEq/L increase in [Na+] was approximately 24 hours in all Vaprisol groups in both studies.

Overall, these two clinical studies demonstrated an overly rapid [Na+] increase in about 5 percent of patients who received Vaprisol for the treatment of hyponatremia. In the RCT, 2 (7 percent) of the 29 patients treated with Vaprisol 40 mg/d, 2 (8 percent) of the 26 treated with Vaprisol 80 mg/d, and 0 of the 29 treated with placebo met the protocol-defined criteria for excessive or overly rapid increase of [Na+]. In the OLS, 1 (3 percent) of 37 patients treated with Vaprisol 20 mg/d and 10 (5 percent) of 214 treated with 40 mg/d met the protocol-defined criteria for excessive or overly rapid increase of [Na+].

None of these patients in either the RCT or the OLS experienced adverse events (AEs) associated with the overly rapid increa
'/>"/>

SOURCE Astellas Pharma US
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. New Way to "See" Genes, Evaluate Effectiveness of Gene Therapies Discovered
2. Inhaled Steroids Safe & Effective for Children with Asthma
3. Morning after pill effective up to five days after having unprotected sex
4. Distraction therapy found very effective in postoperative patients
5. ZD1839 Proves Effective - A Breakthrough in fighting Lung Cancer
6. TELITHROMYCIN - the proven effective new drug for cap
7. Foods Rich In Flavonoids Effective In Prevention Of Cough
8. Looking Towards More Effective Leukemia Treatment
9. Effectiveness of acupuncture for migraines
10. PA-824 drug effective against Tuberculosis
11. Milk Thistle Not An Effective Cure For Liver Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... (PRWEB) May 28, 2015 First ... freestanding emergency rooms in the United States, announced that ... new Denver – Green Valley Ranch facility. , ... increased access to the highest quality emergency medical care ... Valley Ranch facility,” said Dr. James M. Muzzarelli, Executive ...
(Date:5/28/2015)... SpendWell Health, an e-commerce marketplace for ... named a “Cool Vendor” by Gartner in the April ... Payers, 2015 by Jeff Cribbs, Constance Sjoquist, Robert ... vendors, products and services in health care technology—which serve ... care payer market. , SpendWell’s solution delivers the ...
(Date:5/28/2015)... 2015 Peggy J. Lynam, PT, DPT, NCS ... American Physical Therapy Association House of Delegates for the New ... Delegate Assembly. This will be her second term. ... coordinator and principle spokesperson for the Chapter delegation and presides ... or Delegate Assembly may direct the Chief Delegate to present ...
(Date:5/27/2015)... Throughout the past few months, Push to Walk has ... and reliability of the Shaw Gait Assessment in comparison to ... in the Department of Physical Therapy at Seton Hall University ... Gait Assessment is a free online tool, where the GaitRite ... considered the gold standard in providing information about how someone ...
(Date:5/27/2015)... 27, 2015 StatRad, a leading provider ... pleased to introduce Mr. Chris E. Hafey as its ... proven track record of leading new development projects and ... He most recently served as the Chief Technology Officer ... of Chief Architect for Vital Images. , "I am ...
Breaking Medicine News(10 mins):Health News:First Choice Emergency Room to Open New Facility in Denver, Colorado 2Health News:SpendWell Named a “Cool Vendor” by Gartner 2Health News:SpendWell Named a “Cool Vendor” by Gartner 3Health News:SpendWell Named a “Cool Vendor” by Gartner 4Health News:Push to Walk Partners with Seton Hall University for Study 2Health News:StatRad Introduces Mr. Chris E. Hafey as Chief Technology Officer, and the Release of its Advanced Pure HTML5 DICOM Image Uploader 2
... from basic training and now serving overseas, meets the young Korean leukemia patient ... ... Republic of Korea (PRWEB) November 21, 2008 -- A local Korean woman and ... first time when she visited Kunsan Air Base Nov. 21, 2008. , , ...
... be held on January 8, 2009 , ... Med-Emerg International Inc. ("MedEmerg") (OTCBB: MDER), one of Canada,s ... has obtained an interim order from the Ontario Superior ... arrangement (the "Arrangement") pursuant to which AIM Health Group ...
... Heska Corporation,(Nasdaq: HSKA ) today announced ... Analysts, 12th Annual Biotech and Specialty Pharma Conference on,December ... Floor in New York, NY.,The presentation is scheduled to ... and will be available via live webcast and for ...
... Trials showed Banzel proved effective against Lennox-Gastaut syndrome , , ... called Banzel (rufinamide) has been approved as a supplementary ... syndrome, the U.S. Food and Drug Administration announced Friday. ... four-month clinical trial that included patients ages 4 to ...
... NursingCenter.com, the premier site,for online nursing ... been,updated to improve the interactive experience for ... & Wilkins (LWW), NursingCenter.com now,provides over 900 ... 11,000 articles from more than 50 leading ...
... Nov. 21 Today, prescription drugs are the first choice ... chronic conditions. The 50 percent of Americans treated for ... drug spending and 75 percent of all medical costs. ... Medco Health Solutions, Inc. (NYSE: MHS ) significantly ...
Cached Medicine News:Health News:Life-Saving Airman, Leukemia Patient Meet for First Time 2Health News:Life-Saving Airman, Leukemia Patient Meet for First Time 3Health News:Med-Emerg International Inc. obtains interim court order for plan of arrangement with AIM Health Group Inc. 2Health News:Med-Emerg International Inc. obtains interim court order for plan of arrangement with AIM Health Group Inc. 3Health News:FDA Approves New Drug for Severe Epilepsy 2Health News:NursingCenter.com Launches New Features to Improve User Experience 2Health News:NursingCenter.com Launches New Features to Improve User Experience 3Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 2Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 3Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 4Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 5Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 6
(Date:5/28/2015)... , May 28, 2015  Eli Lilly ... results of the Phase III PROCLAIM trial that ... at the American Society of Clinical Oncology (ASCO) ... PROCLAIM was a randomized, Phase III superiority study ... cancer (NSCLC), which evaluated Lilly,s ALIMTA ®  (pemetrexed ...
(Date:5/28/2015)... MOUNTAIN VIEW, Calif. , May 28, 2015 ... healthcare informatics market, Frost & Sullivan recognizes ... Frost & Sullivan Award for Company of the ... effort to take HCM to the next level ... highly strategic acquisitions and followed them up with ...
(Date:5/28/2015)... -- Cypher Genomics, Inc., the leading genome ... announced a collaboration in which Cypher,s automated genomic interpretation ... genetic diseases among a unique population. Located in ... Children (CSC) serves many Amish and Mennonite patients, a ... disease. "We are very excited to ...
Breaking Medicine Technology:PROCLAIM Final Trial Results to be Presented at ASCO Annual Meeting 2PROCLAIM Final Trial Results to be Presented at ASCO Annual Meeting 3PROCLAIM Final Trial Results to be Presented at ASCO Annual Meeting 4PROCLAIM Final Trial Results to be Presented at ASCO Annual Meeting 5PROCLAIM Final Trial Results to be Presented at ASCO Annual Meeting 6PROCLAIM Final Trial Results to be Presented at ASCO Annual Meeting 7PROCLAIM Final Trial Results to be Presented at ASCO Annual Meeting 8Frost & Sullivan Acknowledges Lexmark Healthcare's Energy, Creativity, and Diligence in Developing the Leading Next-Generation Healthcare Content Management Platform 2Frost & Sullivan Acknowledges Lexmark Healthcare's Energy, Creativity, and Diligence in Developing the Leading Next-Generation Healthcare Content Management Platform 3Frost & Sullivan Acknowledges Lexmark Healthcare's Energy, Creativity, and Diligence in Developing the Leading Next-Generation Healthcare Content Management Platform 4Frost & Sullivan Acknowledges Lexmark Healthcare's Energy, Creativity, and Diligence in Developing the Leading Next-Generation Healthcare Content Management Platform 5Cypher Genomics and Clinic for Special Children Collaborate on Rare Disease Study 2Cypher Genomics and Clinic for Special Children Collaborate on Rare Disease Study 3
... , , ... KERX ) today announced results of the Open Label ... of elevated serum phosphorous levels, or hyperphosphatemia, in patients with ... in Taiwan, enrolled 29 of the 37 Taiwanese patients that ...
... , , , ... today announced results from a Phase II trial of regorafenib (BAY 73-4506), ... in a 31 percent partial response rate and 50 percent stabilization rate ... in an oral session at the joint 15th Congress of the European ...
Cached Medicine Technology:Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia 2Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia 3Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia 4Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients 2Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients 3Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients 4
... less than thirty pounds, the EUB 405 ... quality. Compatible with a wide range of ... solution for a variety of clinical settings. ... easy to operate. It includes an alphanumeric ...
... fast, the HI VISION 8500 diagnostic ... with user-oriented operation for exceptional imaging ... package consists of advanced techniques for ... COMPOUND multi-angle spatial compounding, wideband pulse-inversion, ...
... is a radial-type endoscope with a built-in ... a flicker-free, high-resolution image under echo. It ... for direct visual observation. The EG-3630UR has ... an endoscope as well as exceptional ultrasound ...
... The ACL 7000 coagulation analyzer is ... that needs a full range of ... You'll have access to a broad ... APCR-Leiden. Plus, you'll benefit from an ...
Medicine Products: